Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
autologous anti-CD19 (human derived) chimeric antigen receptor T cells / Beijing Boren Hospital
ChiCTR-OIC-17013623: Phase I study of autologous anti-CD19 (mice derived) chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia	Recruiting	1	20		anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy	Beijing Boren Hospital; Beijing Boren Hospital, Beijing Boren Hospital	Relapsed or refractory B acute lymphoblastic leukemia
ChiCTR1900022216: A study for autologous anti-CD19 (mice derived) chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia	Recruiting	N/A	200		D19-cart cell immunotherapy	Beijing Boren Hospital; Beijing Boren Hospital, Beijing Boren Hospital	Relapsed or refractory B acute lymphoblastic leukemia
ChiCTR1900024456: Phase I study for autologous anti-CD19 (human derived) chimeric antigen receptor T cells treating refractory or relapsed acute lymphoblastic leukemia	Recruiting	N/A	20		anti-CD19 (human derived) cell immunotherapy	Beijing Boren Hospital; Beijing Boren Hospital, Beijing Boren Hospital	refractory or relapsed acute lymphoblastic leukemia